title: Antimicrobial Peptides as Anti-Infectives against Staphylococcus epidermidis.
abstract: Staphylococcus epidermidis has emerged as the main causative agent for graft-related and nosocomial infections. Rampant use of antibiotics and biofilm formed by the organism results in poor penetration of the drug and further aggravates the antibiotic resistance, emphasizing an urgent need to explore alternative treatment modalities. Antimicrobial peptides (AMPs), produced as effector molecules of the innate immunity of living organisms, have therapeutic potential that can be used to inhibit the growth of microbes. In addition, the susceptibility of a microbe to become resistant to an AMP is relatively low. The AMPs are amphipathic peptides of 12-100 residues, which have broad-spectrum activity against microbes. There are scattered reports of AMPs listed against S. epidermidis and there is an urgent need to systematically study the AMPs. Various natural AMPs as well as synthetic peptides have been investigated against S. epidermidis. These peptides have been shown to inhibit both planktonic culture and S. epidermidis biofilm effectively. The multiple modes of action in killing the organism minimize the chances for the development of resistance. This review focused on various natural and synthetic peptides that demonstrate activity against S. epidermidis.
authors.affiliation: Department of Biotechnology, Jaypee Institute of Information Technology, Noida, India.
authors.forename: Sangya
authors.initials: S
authors.lastname: Agarwal
authors.forename: Garima
authors.initials: G
authors.lastname: Sharma
authors.forename: Shweta
authors.initials: S
authors.lastname: Dang
authors.forename: Sanjay
authors.initials: S
authors.lastname: Gupta
authors.forename: Reema
authors.initials: R
authors.lastname: Gabrani
mesh_terms: D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides / Q000378:metabolism / Q000494:pharmacology*; D001430:Bacteriocins / Q000494:pharmacology; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development; D015195:Drug Design; D006801:Humans; D009842:Oligopeptides / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000494:pharmacology; D011506:Proteins / Q000494:pharmacology; D013212:Staphylococcus epidermidis / Q000187:drug effects*
chemical_list: D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D001430:Bacteriocins; C495931:Jelleine I; C495932:Jelleine II; C495933:Jelleine III; D009842:Oligopeptides; D010456:Peptides, Cyclic; D011506:Proteins; C097849:buforin II; C574453:epidermicin NI01, Staphylococcus epidermidis; C086618:ranalexin